MX2020002898A - Formulaciones topicas de cloroprocaina y metodos para utilizar las mismas. - Google Patents

Formulaciones topicas de cloroprocaina y metodos para utilizar las mismas.

Info

Publication number
MX2020002898A
MX2020002898A MX2020002898A MX2020002898A MX2020002898A MX 2020002898 A MX2020002898 A MX 2020002898A MX 2020002898 A MX2020002898 A MX 2020002898A MX 2020002898 A MX2020002898 A MX 2020002898A MX 2020002898 A MX2020002898 A MX 2020002898A
Authority
MX
Mexico
Prior art keywords
chloroprocaine
methods
same
topical formulations
formulations
Prior art date
Application number
MX2020002898A
Other languages
English (en)
Spanish (es)
Inventor
Clara Bianchi
Elisabetta Donati
Augusto Mitidieri
Original Assignee
Sintetica S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sintetica S A filed Critical Sintetica S A
Publication of MX2020002898A publication Critical patent/MX2020002898A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245Amino benzoic acid types, e.g. procaine, novocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • A61P23/02Local anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2020002898A 2017-09-15 2018-09-14 Formulaciones topicas de cloroprocaina y metodos para utilizar las mismas. MX2020002898A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762559220P 2017-09-15 2017-09-15
PCT/IB2018/057073 WO2019053657A1 (en) 2017-09-15 2018-09-14 TOPICAL FORMULATIONS OF CHLOROPROCAINE

Publications (1)

Publication Number Publication Date
MX2020002898A true MX2020002898A (es) 2020-11-06

Family

ID=63713967

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002898A MX2020002898A (es) 2017-09-15 2018-09-14 Formulaciones topicas de cloroprocaina y metodos para utilizar las mismas.

Country Status (22)

Country Link
US (3) US10792271B2 (https=)
EP (1) EP3681473A1 (https=)
JP (1) JP2020533321A (https=)
KR (1) KR102759903B1 (https=)
CN (1) CN111163756B (https=)
AU (1) AU2018332212B2 (https=)
CA (1) CA3070336C (https=)
CL (1) CL2020000665A1 (https=)
CO (1) CO2020002985A2 (https=)
CR (1) CR20200133A (https=)
CU (1) CU20200019A7 (https=)
EA (1) EA202090735A1 (https=)
EC (1) ECSP20022313A (https=)
IL (1) IL273213B2 (https=)
JO (1) JOP20200010A1 (https=)
MA (1) MA50241A (https=)
MX (1) MX2020002898A (https=)
PE (1) PE20201281A1 (https=)
PH (1) PH12020550029A1 (https=)
SG (1) SG11202000992RA (https=)
WO (1) WO2019053657A1 (https=)
ZA (1) ZA202000601B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202139993A (zh) * 2020-03-16 2021-11-01 瑞士商辛鐵堤卡公司 具有經改良之功能性的眼用氯普魯卡因(chloroprocaine)凝膠

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR930000050B1 (ko) * 1990-08-29 1993-01-06 브리스톨-마이어즈 스퀴브 컴페니 항균제 겔 배합물
US6218428B1 (en) * 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
JP2004123634A (ja) * 2002-10-03 2004-04-22 Lion Corp 眼科用組成物
WO2004058329A2 (en) * 2002-12-20 2004-07-15 The Board Of Trustees Of The Leland Stanford Junior University Ester combination local anesthetic
US20050137177A1 (en) 2003-12-18 2005-06-23 Shafer Steven L. Ester combination local anesthetic
EA200701131A1 (ru) * 2004-11-24 2007-12-28 Алгоркс Фармасьютикалз, Инк. Гелеобразная препаративная форма капсаициноида и способы её применения
ITMI20051633A1 (it) 2005-09-06 2007-03-07 Sint Sa Nuovo uso di una composizione comprendente cloroprocaina hcl nuova composizione comprendente cloroprocaina hcl e metodo per la sua fabbricazione
ITMI20122120A1 (it) * 2012-12-12 2014-06-13 Sint Sa Composizione farmaceutica a base di cloroprocaina per la somministrazione intratecale ripetuta
CN103405576B (zh) * 2013-08-23 2016-03-30 何学忠 一种治疗由焊接强光辐射引起的眼部疾病的滴眼液

Also Published As

Publication number Publication date
EP3681473A1 (en) 2020-07-22
JP2020533321A (ja) 2020-11-19
IL273213B2 (en) 2025-06-01
IL273213B1 (en) 2025-02-01
KR20200053476A (ko) 2020-05-18
AU2018332212A1 (en) 2020-02-27
CA3070336C (en) 2022-08-23
CU20200019A7 (es) 2020-11-30
WO2019053657A1 (en) 2019-03-21
IL273213A (en) 2020-04-30
AU2018332212B2 (en) 2023-03-16
KR102759903B1 (ko) 2025-01-23
US11969403B2 (en) 2024-04-30
EA202090735A1 (ru) 2020-06-22
US20190083446A1 (en) 2019-03-21
US10792271B2 (en) 2020-10-06
BR112020003095A2 (pt) 2020-08-25
CL2020000665A1 (es) 2020-09-21
SG11202000992RA (en) 2020-03-30
JOP20200010A1 (ar) 2020-01-22
CA3070336A1 (en) 2019-03-21
CN111163756A (zh) 2020-05-15
ZA202000601B (en) 2021-02-24
PH12020550029A1 (en) 2021-02-08
CO2020002985A2 (es) 2020-05-29
ECSP20022313A (es) 2020-07-31
CN111163756B (zh) 2022-04-15
US20200390738A1 (en) 2020-12-17
US20240216323A1 (en) 2024-07-04
MA50241A (fr) 2020-07-22
CR20200133A (es) 2020-05-09
PE20201281A1 (es) 2020-11-24

Similar Documents

Publication Publication Date Title
CO2023010562A2 (es) Degradadores irak4 y usos de los mismos
CL2017002727A1 (es) Composiciones de ácido obeticólico y métodos de uso
CR20160130A (es) Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
MX2016015636A (es) Formulaciones cannabinoides estables.
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
CR20130033A (es) Formulaciones de rifaximina y usos de las mismas
ECSP21030482A (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
MX2019001877A (es) Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
CL2011002675A1 (es) Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende.
UY35535A (es) ?Derivados de fenil sulfonamidas?.
CO2017002506A2 (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
BR112022012205A2 (pt) Compostos ativos para receptores nucleares
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
CO2019009020A2 (es) Derivados de pirazol como inhibidores de bromodominio.
CL2021003228A1 (es) Compuestos tricíclicos y su uso
UY35536A (es) ?derivados de sulfonamida?.
ECSP20022313A (es) Formulaciones tópicas de cloroprocaína y métodos para utilizar las mismas
UY37261A (es) Formulación combinada de tres compuestos antivirales
PY2018665A (es) Formulaciones tópicas de cloroprocaína y métodos para utilizar las mismas
UY38606A (es) Formulaciones tópicas de cloroprocaína y métodos para utilizar las mismas
CL2018002010A1 (es) Derivados de indano y su uso en terapias.
UY36958A (es) Compuestos para administración intracelular
CO2017002963A2 (es) Espiro-tiazolonas